Agreement ensures consistent supply of nucleotides, enzymes and other critical raw materials for messenger RNA (mRNA) vaccine manufacturing platform
WALTHAM, Mass./PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it has signed a multi-year agreement with Mainz, Germany-based BioNTech focused on supplying critical raw materials for the manufacturing of precise immunotherapy vaccine candidates.
Under the agreement, Thermo Fisher will supply nucleotides, enzymes and other critical raw materials to support BioNTech's messenger RNA (mRNA) manufacturing platform. The four-year, nonexclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher'stechnologies as part of its clinical and commercial manufacturing processes.
"Our portfolio of molecular biology products is now enabling development and commercialization of multiple individualized therapies and other advanced medicines and we continue to expand our capabilities to meet increasing demand," said Gianluca Pettiti, president, biosciences, Thermo Fisher Scientific. "We share BioNTech's commitment to deliver life-saving therapies to patients faster, and we look forward to supporting them through clinical trials and post-approval production."
"The relationship with Thermo Fisher Scientific secures our access to customized material essential for the manufacturing and commercialization of our RNA-based product candidates," said Ugur Sahin, M.D., co-founder and CEO of BioNTech. "In addition, as a life science services leader, Thermo Fisher can also deliver reagents at the scale needed to expand our manufacturing capacities."
No other terms from this transaction were disclosed.
Media Contact Information:
Ron O'Brien
Thermo Fisher Scientific
781-622-1242
ron.obrien@thermofisher.com
